Author(s): AFZAL SHAH | ABDUR RAU | ASAD ULLAH | AZEEMA MUNIR | RUMANA QURESHI | IFTIKHAR AHMAD | MUHAMMAD TAHIR SOOMRO | ZIA-UR-REHMAN
Journal: Journal of Electrochemical Science and Engineering
ISSN 1847-9286
Volume: 3;
Issue: 1;
Start page: 19;
Date: 2013;
VIEW PDF
DOWNLOAD PDF 
Original page
Keywords: Anthraquinones | redox mechanism | voltammetry | binding constant
ABSTRACT
The redox behaviour of two potential anticancer anthraquinones, 9,10-anthraquinone and 2-chloromethyl-9,10-anthraquinone was investigated in a wide pH range. Cyclic voltammetry based assay was developed for the assessment of the effect of medium, substituents, potential scan rate and number of scans on the voltammetric response of anthraquinones. The electrode reaction mechanism was suggested on the basis of cyclic and differential pulse voltammetric results. The effect of DNA on anthraquinones was also probed at physiological pH which could lead to further investigation of possible citotoxic activity in vitro. The results revealed that anthraquinones interact with DNA more strongly than the clinically used anticancer drug, epirubicin.
Journal: Journal of Electrochemical Science and Engineering
ISSN 1847-9286
Volume: 3;
Issue: 1;
Start page: 19;
Date: 2013;
VIEW PDF
DOWNLOAD PDF Original pageKeywords: Anthraquinones | redox mechanism | voltammetry | binding constant
ABSTRACT
The redox behaviour of two potential anticancer anthraquinones, 9,10-anthraquinone and 2-chloromethyl-9,10-anthraquinone was investigated in a wide pH range. Cyclic voltammetry based assay was developed for the assessment of the effect of medium, substituents, potential scan rate and number of scans on the voltammetric response of anthraquinones. The electrode reaction mechanism was suggested on the basis of cyclic and differential pulse voltammetric results. The effect of DNA on anthraquinones was also probed at physiological pH which could lead to further investigation of possible citotoxic activity in vitro. The results revealed that anthraquinones interact with DNA more strongly than the clinically used anticancer drug, epirubicin.
